Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential

被引:3
|
作者
Voutsadakis, Ioannis A. [1 ,2 ]
机构
[1] Sault Area Hosp, Algoma Dist Canc Program, 750 Great Northern Rd, Sault Ste Marie, ON P6B 0A8, Canada
[2] Northern Ontario Sch Med, Div Clin Sci, Sect Internal Med, Sudbury, ON P3E 2C6, Canada
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 10期
关键词
colon cancer; cell line models; dependencies; targeted therapy; signal transduction; GENOMIC LANDSCAPE; EXPRESSION; SPECIFICITY; ENCORAFENIB; ACTIVATION; CETUXIMAB; PATHWAY; ARK5;
D O I
10.3390/medicina58101498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Colorectal cancer represents a common malignancy and remains incurable in the metastatic stage. Identification of molecular alterations that are present in colorectal cancer has led to the introduction of targeted therapies that improve outcomes. BRAF and PIK3CA mutations are observed in a subset of colorectal cancers. Colorectal cancers bearing BRAF mutations may be treated with specific BRAF inhibitors. These drugs benefit patients with BRAF mutant colorectal cancers but responses are rather brief, and progression is the rule. In contrast, no PI3K inhibitors have proven successful yet in the disease. Thus, new treatments to supplement the currently available drugs would be welcome to further improve survival. Methods: Profiled colorectal cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were examined for BRAF and PIK3CA mutations and were interrogated for molecular characteristics and concomitant alterations that mirror clinical sample alterations. The Genomics of Drug Sensitivity in Cancer (GDSC) project was used for determination of drug sensitivities of BRAF mutated colorectal cell lines with or without concomitant PIK3CA mutations. The Cancer Dependency Map project served as the basis for identification of molecular dependencies and vulnerabilities in these cell lines. Results: CCLE includes 84 colorectal cancer cell lines, which recapitulate the molecular landscape of colorectal cancer. Of these, 23 and 24 cell lines possess BRAF and PIK3CA mutations, respectively. Seven BRAF mutant cell lines have V600E mutations and 14 PIK3CA mutant cell lines have hotspot helical or kinase domain mutations. V600E BRAF mutant cell lines with or without hotspot PIK3CA mutations are heterogeneous in their MSI status and mimic colorectal cancer tissues in other prevalent abnormalities including APC and TP53 mutations. Essential genes for survival include CTNNB1, WRN, and pyrimidine metabolism enzyme CAD. Besides BRAF mutations, BRAF inhibitor sensitivity in colorectal cancer cell lines is conferred by SACS mutations and PRKN locus loss. Conclusions: Colorectal cancer cell lines bearing the frequent BRAF and PIK3CA mutations present many alterations of the parental cancer tissue. Described vulnerabilities represent leads for therapeutic exploration in colorectal cancers with the corresponding alterations.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer
    Li, Hong-Tao
    Lu, Yuan-Yuan
    An, Yan-Xin
    Wang, Xin
    Zhao, Qing-Chuan
    ONCOLOGY REPORTS, 2011, 25 (06) : 1691 - 1697
  • [2] Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond
    Katsios, Christos
    Ziogas, Dimosthenis E.
    Roukos, Dimitrios H.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (05) : 525 - 529
  • [3] The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
    Eklof, V.
    Wikberg, M. L.
    Edin, S.
    Dahlin, A. M.
    Jonsson, B-A
    Oberg, A.
    Rutegard, J.
    Palmqvist, R.
    BRITISH JOURNAL OF CANCER, 2013, 108 (10) : 2153 - 2163
  • [4] Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients
    Emelyanova, M. A.
    Amossenko, F. A.
    Semyanikhina, A. V.
    Aliev, V. A.
    Barsukov, Yu. A.
    Lyubchenko, L. N.
    Nasedkina, T. V.
    MOLECULAR BIOLOGY, 2015, 49 (04) : 550 - 559
  • [5] The Landscape of PIK3CA Mutations in Colorectal Cancer
    Voutsadakis, Ioannis A.
    CLINICAL COLORECTAL CANCER, 2021, 20 (03) : 201 - 215
  • [6] Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
    Foltran, Luisa
    De Maglio, Giovanna
    Pella, Nicoletta
    Ermacora, Paola
    Aprile, Giuseppe
    Masiero, Elena
    Giovannoni, Mariella
    Iaiza, Emiliana
    Cardellino, Giovanni Gerardo
    Lutrino, Stefania Eufemia
    Mazzer, Micol
    Giangreco, Manuela
    Pisa, Federica Edith
    Pizzolitto, Stefano
    Fasola, Gianpiero
    FUTURE ONCOLOGY, 2015, 11 (04) : 629 - 640
  • [7] Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer
    Lu, Weipeng
    Wei, Hong
    Li, Mei
    Wang, Hai
    Liu, Lina
    Zhang, Qiuping
    Liu, Lisha
    Lu, Shen
    MOLECULAR MEDICINE REPORTS, 2015, 12 (01) : 1219 - 1224
  • [8] Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Martinelli, E.
    Fenizia, F.
    Esposito, C.
    Roma, C.
    Troiani, T.
    Rizzi, D.
    Tatangelo, F.
    Botti, G.
    Maiello, E.
    Colucci, G.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1710 - 1714
  • [9] The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
    Wang, Haitao
    Tang, Rui
    Jiang, Ling
    Jia, Yingtian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population
    Herreros-Villanueva, Marta
    Gomez-Manero, Noemi
    Muniz, Pilar
    Garcia-Giron, Carlos
    Jesus Coma del Corral, Maria
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (02) : 1347 - 1351